Effect of resveratrol associated with eriodontal treatment of patients with aggressive periodontitis.

Not Applicable

• Conditions: Periodontal diseases; C07.465.714

• Registration Number: RBR-5hjcyb
• Lead Sponsor: niversidade Paulista

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-03-10
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Diagnosis of generalized aggressive periodontitis verified by the presence
of true periodontal pockets and radiographic bone loss in patients up to 35 years of age, according to the criteria established by the Academy American Periodontics in 1999; Presence of at least eight teeth with probing depth equal to or above 5 mm (of which two teeth should have probing pocket depth iqual to or above 7 mm) and bleeding on probing;
Presence of at least 20 teeth in the oral cavity; Group approaches: Presence of at least two residual periodontal pockets, on posterior teeth without furcation involvement, with probing depth iqual to or above 5 mm and bleeding on probing, three months after non-surgical periodontal treatment.

Exclusion Criteria

Periodontal treatment in the 6 months prior to the study; Use of medications, such as antibiotics, anti-inflammatory drugs
continuous use, phenytoin, cyclosporine, in the 6 months prior to the study; Presence of systemic changes or active infectious disease (diabetes, heart disease, hepatitis, etc.);
Presence of smoking habit; Pregnancy or breastfeeding; Group approaches: Presence of furcation injury; Presence of periapical or pulp changes; Presence of systemic changes or use of medications (6 months prior to the study) that may influence the response to periodontal treatment; Smoking patients; pregnant patients; Patients taking medications such as corticosteroids and antibiotics.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected a gain in clinical attachment level and a reduciton in probing pocket depth in the group treated with resveratrol comparedo to the placebo grop, by means of clinical measurement of clinical attachement level and pocket depth using a periodontal probe. <br><br>Group approaches: it is expected greater gain in the clinical attachment level and lower pocket depth in the groups receiving photodynamic therapy.

Secondary Outcome Measures

Name	Time	Method
It is expected reduction in the production of pro-inflammatory factors and increase in the production of anit-inflammatory factors in the group treated with resveratrol compared to the placebo group, through the quantification of inflammatory factors, using the immunoenzimatic assay.